PhaseBio Pharmaceuticals Inc (PHASQ) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
1 GREAT VALLEY PARKWAY MALVERN, PA 19355 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 18,688 | 41,800 | 56,357 | 64,456 | 76,963 | 28,122 | |||
| Cash and cash equivalents | 18,688 | 41,800 | 56,357 | 64,456 | 76,963 | 28,122 | |||
| Contract with customer, asset, after allowance for credit loss | 18,400 | ||||||||
| Other undisclosed current assets | 8,881 | 6,984 | 8,884 | 5,644 | 11,194 | 12,027 | |||
| Total current assets: | 27,569 | 48,784 | 65,241 | 88,500 | 88,157 | 40,149 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,341 | 1,469 | 1,586 | 1,701 | 1,815 | 1,927 | |||
| Property, plant and equipment | 9,697 | 10,230 | 10,841 | 10,379 | 10,792 | 8,224 | |||
| Other noncurrent assets | 57 | 57 | 57 | 57 | 57 | 57 | |||
| Total noncurrent assets: | 11,095 | 11,756 | 12,484 | 12,137 | 12,664 | 10,208 | |||
| TOTAL ASSETS: | 38,664 | 60,540 | 77,725 | 100,637 | 100,821 | 50,357 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 10,129 | 20,923 | 10,887 | 4,969 | 7,863 | 9,605 | |||
| Interest and dividends payable | 31 | 44 | 52 | 61 | |||||
| Employee-related liabilities | 1,348 | 1,841 | 1,483 | 1,223 | |||||
| Accounts payable | 6,778 | 12,570 | 8,521 | 2,958 | 5,898 | 3,674 | |||
| Accrued liabilities | 1,972 | 8,353 | 481 | 476 | 681 | 5,931 | |||
| Deferred revenue | 1,594 | 1,547 | 1,414 | 1,424 | |||||
| Debt | 5,425 | 5,413 | 5,399 | 5,384 | 5,370 | 5,355 | |||
| Other undisclosed current liabilities | 4,540 | 3,757 | 4,397 | 3,435 | |||||
| Total current liabilities: | 21,688 | 27,883 | 21,457 | 16,174 | 16,668 | 14,960 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 969 | 2,432 | 3,900 | 5,379 | 6,853 | 8,321 | |||
| Long-term debt, excluding current maturities | 1,359 | 2,718 | 4,073 | 5,425 | 6,773 | ||||
| Liabilities, other than long-term debt | 118,402 | 123,259 | 102,697 | 98,259 | 68,889 | 52,278 | |||
| Deferred revenue | 7,458 | 7,622 | 7,913 | 8,238 | |||||
| Other liabilities | 794 | 747 | 692 | 629 | 559 | ||||
| Operating lease, liability | 969 | 1,073 | 1,182 | 1,306 | 1,428 | 1,548 | |||
| Derivative instruments and hedges, liabilities | 110,944 | 114,843 | 94,037 | 89,329 | 68,260 | 51,719 | |||
| Total noncurrent liabilities: | 119,371 | 125,691 | 106,597 | 103,638 | 75,742 | 60,599 | |||
| Total liabilities: | 141,059 | 153,574 | 128,054 | 119,812 | 92,410 | 75,559 | |||
| Equity | |||||||||
| Equity, attributable to parent | (102,395) | (93,034) | (50,329) | (19,175) | 8,411 | (25,202) | |||
| Common stock | 49 | 48 | 48 | 48 | 48 | 29 | |||
| Treasury stock, value | (24) | (24) | (24) | (24) | (24) | (24) | |||
| Additional paid in capital | 300,515 | 298,736 | 298,331 | 297,561 | 296,468 | 235,516 | |||
| Accumulated deficit | (402,935) | (391,794) | (348,684) | (316,760) | (288,081) | (260,723) | |||
| Total equity: | (102,395) | (93,034) | (50,329) | (19,175) | 8,411 | (25,202) | |||
| TOTAL LIABILITIES AND EQUITY: | 38,664 | 60,540 | 77,725 | 100,637 | 100,821 | 50,357 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 117 | 158 | 335 | 10,338 | ||||
| Gross profit: | 117 | 158 | 335 | 10,338 | ||||
| Operating expenses | (18,345) | (32,244) | (28,911) | (31,391) | (25,647) | (25,978) | ||
| Operating loss: | (18,228) | (32,086) | (28,576) | (21,053) | (25,647) | (25,978) | ||
| Nonoperating income (expense) | 7,089 | (11,024) | (3,348) | (6,026) | (1,711) | (4,396) | ||
| Other nonoperating income (expense) | 7,087 | (11,024) | (3,348) | (6,026) | (1,711) | (4,397) | ||
| Interest and debt expense | (148) | (186) | (222) | (254) | (285) | (326) | ||
| Loss from continuing operations before equity method investments, income taxes: | (11,287) | (43,296) | (32,146) | (27,333) | (27,643) | (30,700) | ||
| Other undisclosed income from continuing operations before income taxes | 186 | 222 | 254 | |||||
| Loss from continuing operations before income taxes: | (11,287) | (43,110) | (31,924) | (27,079) | (27,643) | (30,700) | ||
| Income tax expense | (1,600) | |||||||
| Loss from continuing operations: | (11,287) | (43,110) | (31,924) | (28,679) | (27,643) | (30,700) | ||
| Loss before gain (loss) on sale of properties: | (11,287) | (43,110) | (31,924) | (28,679) | (27,643) | (30,700) | ||
| Other undisclosed net income | 146 | 285 | 325 | |||||
| Net loss available to common stockholders, diluted: | (11,141) | (43,110) | (31,924) | (28,679) | (27,358) | (30,375) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (11,141) | (43,110) | (31,924) | (28,679) | (27,358) | (30,375) | ||
| Comprehensive loss, net of tax, attributable to parent: | (11,141) | (43,110) | (31,924) | (28,679) | (27,358) | (30,375) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.